Zacks Investment Research Lowers Glanbia (OTCMKTS:GLAPY) to Sell

Glanbia (OTCMKTS:GLAPY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Glanbia Plc engages in the manufacture and distribution of dairy and nutritional food products. Its operating segments include Glanbia Performance Nutrition, Global Ingredients, Dairy Ireland and Joint Ventures and Associates. Glanbia Performance Nutrition segment comprises of performance nutrition products under the Optimum Nutrition, BSN, Isopure, Nutramino and ABB brands. Global Ingredients segment includes American-style cheddar cheese, micro-nutrient premixes and dairy and non-dairy nutritional solutions. Dairy Ireland segment consists of consumer products and agribusiness. Joint Ventures and Associates segment covers Glanbia Ingredients Ireland, Glanbia Cheese and Southwest Cheese. Glanbia Plc is headquartered in Kilkenny, Ireland. “

GLAPY stock remained flat at $$59.01 during mid-day trading on Tuesday. Glanbia has a 52-week low of $53.60 and a 52-week high of $107.19. The company has a market capitalization of $3.49 billion, a P/E ratio of 10.99, a price-to-earnings-growth ratio of 1.84 and a beta of 0.24. The stock has a fifty day moving average of $58.33 and a 200-day moving average of $63.70.

About Glanbia

Glanbia plc operates as a nutrition company worldwide. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, the Internet, and gyms, as well the food, drug, mass, and club channels.

See Also: What are the benefits of a portfolio tracker?

Get a free copy of the Zacks research report on Glanbia (GLAPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with MarketBeat.com's FREE daily email newsletter.